FDA Approval Insights: Selpercatinib in RET Fusion–Positive Solid Tumors

Dr Subbiah discusses the significance of the FDA approval of selpercatinib in RET fusion–positive non–small cell lung cancer, thyroid cancer, and other solid tumors.